These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 36947031

  • 1. Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020.
    Jacobs JA, Addo DK, Zheutlin AR, Derington CG, Essien UR, Navar AM, Hernandez I, Lloyd-Jones DM, King JB, Rao S, Herrick JS, Bress AP, Pandey A.
    JAMA Cardiol; 2023 May 01; 8(5):443-452. PubMed ID: 36947031
    [Abstract] [Full Text] [Related]

  • 2. Atherosclerotic Cardiovascular Disease Risk Estimates Using the Predicting Risk of Cardiovascular Disease Events Equations.
    Anderson TS, Wilson LM, Sussman JB.
    JAMA Intern Med; 2024 Aug 01; 184(8):963-970. PubMed ID: 38856978
    [Abstract] [Full Text] [Related]

  • 3. Disparities in Guideline-Recommended Statin Use for Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and Gender : A Nationally Representative Cross-Sectional Analysis of Adults in the United States.
    Frank DA, Johnson AE, Hausmann LRM, Gellad WF, Roberts ET, Vajravelu RK.
    Ann Intern Med; 2023 Aug 01; 176(8):1057-1066. PubMed ID: 37487210
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cardiovascular Disease Risk Assessment Using Traditional Risk Factors and Polygenic Risk Scores in the Million Veteran Program.
    Vassy JL, Posner DC, Ho YL, Gagnon DR, Galloway A, Tanukonda V, Houghton SC, Madduri RK, McMahon BH, Tsao PS, Damrauer SM, O'Donnell CJ, Assimes TL, Casas JP, Gaziano JM, Pencina MJ, Sun YV, Cho K, Wilson PWF.
    JAMA Cardiol; 2023 Jun 01; 8(6):564-574. PubMed ID: 37133828
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparing eligibility for statin therapy for primary prevention under 2022 USPSTF recommendations and the 2018 AHA/ACC/ multi-society guideline recommendations: From National Health and Nutrition Examination Survey.
    Gupta K, Kakar TS, Jain V, Gupta M, Al Rifai M, Slipczuk L, Nambi V, Bittner V, Blumenthal RS, Stone NJ, Lavie CJ, Virani SS.
    Prog Cardiovasc Dis; 2022 Jun 01; 75():78-82. PubMed ID: 36038004
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Ethnic differences in guideline-indicated statin initiation for people with type 2 diabetes in UK primary care, 2006-2019: A cohort study.
    Eastwood SV, Mathur R, Sattar N, Smeeth L, Bhaskaran K, Chaturvedi N.
    PLoS Med; 2021 Jun 01; 18(6):e1003672. PubMed ID: 34185782
    [Abstract] [Full Text] [Related]

  • 11. Age-based disparities in statin use for primary prevention in US adults: National Health and Nutrition Examination Surveys 2013-2020.
    Zheutlin AR, Jacobs JA, Derington CG, Chaitoff A, Navar AM, Bress AP.
    J Clin Lipidol; 2023 Jun 01; 17(5):688-693. PubMed ID: 37599197
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prevalence and Factors Associated With Statin Use Among a Nationally Representative Sample of US Adults: National Health and Nutrition Examination Survey, 2011-2012.
    Adedinsewo D, Taka N, Agasthi P, Sachdeva R, Rust G, Onwuanyi A.
    Clin Cardiol; 2016 Sep 01; 39(9):491-6. PubMed ID: 27505443
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
    Kohli-Lynch CN, Bellows BK, Thanassoulis G, Zhang Y, Pletcher MJ, Vittinghoff E, Pencina MJ, Kazi D, Sniderman AD, Moran AE.
    JAMA Cardiol; 2019 Oct 01; 4(10):969-977. PubMed ID: 31461121
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Financial resources, access to care, and quality of care mediate racial disparities in statin usage for secondary prevention.
    Wong C, Marrast L, Rasul R, Srivastava R, Kuvin J, Roswell R, Conigliaro J, Kim EJ.
    PLoS One; 2024 Oct 01; 19(10):e0311724. PubMed ID: 39378232
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
    Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA.
    JAMA; 2015 Jul 14; 314(2):142-50. PubMed ID: 26172894
    [Abstract] [Full Text] [Related]

  • 19. Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014.
    Fan W, Philip S, Granowitz C, Toth PP, Wong ND.
    Diabetes Care; 2019 Dec 14; 42(12):2307-2314. PubMed ID: 31575639
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.